296 related articles for article (PubMed ID: 23617697)
21. Effects of JS-K, a novel anti-cancer nitric oxide prodrug, on gene expression in human hepatoma Hep3B cells.
Dong R; Wang X; Wang H; Liu Z; Liu J; Saavedra JE
Biomed Pharmacother; 2017 Apr; 88():367-373. PubMed ID: 28122301
[TBL] [Abstract][Full Text] [Related]
22. Diazeniumdiolated carbamates: a novel class of nitric oxide donors.
Nandurdikar RS; Maciag AE; Cao Z; Keefer LK; Saavedra JE
Bioorg Med Chem; 2012 Mar; 20(6):2025-9. PubMed ID: 22356735
[TBL] [Abstract][Full Text] [Related]
23. Inhibitory effect of oleanolic acid on hepatocellular carcinoma via ERK-p53-mediated cell cycle arrest and mitochondrial-dependent apoptosis.
Wang X; Bai H; Zhang X; Liu J; Cao P; Liao N; Zhang W; Wang Z; Hai C
Carcinogenesis; 2013 Jun; 34(6):1323-30. PubMed ID: 23404993
[TBL] [Abstract][Full Text] [Related]
24. JS-K, a glutathione S-transferase-activated nitric oxide donor with antineoplastic activity in malignant gliomas.
Weyerbrock A; Osterberg N; Psarras N; Baumer B; Kogias E; Werres A; Bette S; Saavedra JE; Keefer LK; Papazoglou A
Neurosurgery; 2012 Feb; 70(2):497-510; discussion 510. PubMed ID: 21849924
[TBL] [Abstract][Full Text] [Related]
25. A glutathione S-transferase pi-activated prodrug causes kinase activation concurrent with S-glutathionylation of proteins.
Townsend DM; Findlay VJ; Fazilev F; Ogle M; Fraser J; Saavedra JE; Ji X; Keefer LK; Tew KD
Mol Pharmacol; 2006 Feb; 69(2):501-8. PubMed ID: 16288082
[TBL] [Abstract][Full Text] [Related]
26. Synthesis, nitric oxide release, and anti-leukemic activity of glutathione-activated nitric oxide prodrugs: Structural analogues of PABA/NO, an anti-cancer lead compound.
Chakrapani H; Wilde TC; Citro ML; Goodblatt MM; Keefer LK; Saavedra JE
Bioorg Med Chem; 2008 Mar; 16(5):2657-64. PubMed ID: 18060792
[TBL] [Abstract][Full Text] [Related]
27. Design, synthesis, and antihepatocellular carcinoma activity of nitric oxide releasing derivatives of oleanolic acid.
Chen L; Zhang Y; Kong X; Lan E; Huang Z; Peng S; Kaufman DL; Tian J
J Med Chem; 2008 Aug; 51(15):4834-8. PubMed ID: 18598019
[TBL] [Abstract][Full Text] [Related]
28. Oleanolic acid-NO donor-platinum(II) trihybrid molecules: Targeting cytotoxicity on hepatoma cells with combined action mode and good safety.
Fang L; Feng M; Chen F; Liu X; Shen H; Zhao J; Gou S
Bioorg Med Chem; 2016 Oct; 24(19):4611-4619. PubMed ID: 27501909
[TBL] [Abstract][Full Text] [Related]
29. Cell-permeable esters of diazeniumdiolate-based nitric oxide prodrugs.
Chakrapani H; Maciag AE; Citro ML; Keefer LK; Saavedra JE
Org Lett; 2008 Nov; 10(22):5155-8. PubMed ID: 18956868
[TBL] [Abstract][Full Text] [Related]
30. Nitric oxide (NO) releasing poly ADP-ribose polymerase 1 (PARP-1) inhibitors targeted to glutathione S-transferase P1-overexpressing cancer cells.
Maciag AE; Holland RJ; Kim Y; Kumari V; Luthers CE; Sehareen WS; Biswas D; Morris NL; Ji X; Anderson LM; Saavedra JE; Keefer LK
J Med Chem; 2014 Mar; 57(6):2292-302. PubMed ID: 24521039
[TBL] [Abstract][Full Text] [Related]
31. Nitroreductase-activated nitric oxide (NO) prodrugs.
Sharma K; Sengupta K; Chakrapani H
Bioorg Med Chem Lett; 2013 Nov; 23(21):5964-7. PubMed ID: 24050886
[TBL] [Abstract][Full Text] [Related]
32. Novel nitric oxide-releasing derivatives of farnesylthiosalicylic acid: synthesis and evaluation of antihepatocellular carcinoma activity.
Ling Y; Ye X; Zhang Z; Zhang Y; Lai Y; Ji H; Peng S; Tian J
J Med Chem; 2011 May; 54(9):3251-9. PubMed ID: 21504204
[TBL] [Abstract][Full Text] [Related]
33. Synthesis and anti-human hepatocellular carcinoma activity of new nitric oxide-releasing glycosyl derivatives of oleanolic acid.
Huang Z; Zhang Y; Zhao L; Jing Y; Lai Y; Zhang L; Guo Q; Yuan S; Zhang J; Chen L; Peng S; Tian J
Org Biomol Chem; 2010 Feb; 8(3):632-9. PubMed ID: 20090981
[TBL] [Abstract][Full Text] [Related]
34. Diazen-1-ium-1,2-diolated nitric oxide donor ester prodrugs of 5-(4-carboxymethylphenyl)-1-(4-methanesulfonylphenyl)-3-trifluoromethyl-1H-pyrazole and its aminosulfonyl analog: Synthesis, biological evaluation and nitric oxide release studies.
Abdellatif KR; Chowdhury MA; Dong Y; Das D; Yu G; Velázquez C; Suresh MR; Knaus EE
Bioorg Med Chem; 2009 Jul; 17(14):5182-8. PubMed ID: 19500994
[TBL] [Abstract][Full Text] [Related]
35. The nitric oxide prodrug JS-K and its structural analogues as cancer therapeutic agents.
Maciag AE; Saavedra JE; Chakrapani H
Anticancer Agents Med Chem; 2009 Sep; 9(7):798-803. PubMed ID: 19538173
[TBL] [Abstract][Full Text] [Related]
36. The Nitric Oxide Prodrug JS-K Induces Ca(2+)-Mediated Apoptosis in Human Hepatocellular Carcinoma HepG2 Cells.
Liu L; Wang D; Wang J; Wang S
J Biochem Mol Toxicol; 2016 Apr; 30(4):192-9. PubMed ID: 26616367
[TBL] [Abstract][Full Text] [Related]
37. The nitric oxide prodrug JS-K is effective against non-small-cell lung cancer cells in vitro and in vivo: involvement of reactive oxygen species.
Maciag AE; Chakrapani H; Saavedra JE; Morris NL; Holland RJ; Kosak KM; Shami PJ; Anderson LM; Keefer LK
J Pharmacol Exp Ther; 2011 Feb; 336(2):313-20. PubMed ID: 20962031
[TBL] [Abstract][Full Text] [Related]
38. JS-K as a nitric oxide donor induces apoptosis via the ROS/Ca
Huang Z; Liu L; Chen J; Cao M; Wang J
Biomed Pharmacother; 2018 Nov; 107():1385-1392. PubMed ID: 30257354
[TBL] [Abstract][Full Text] [Related]
39. Second-generation aspirin and indomethacin prodrugs possessing an O(2)-(acetoxymethyl)-1-(2-carboxypyrrolidin-1-yl)diazenium-1,2-diolate nitric oxide donor moiety: design, synthesis, biological evaluation, and nitric oxide release studies.
Velázquez CA; Chen QH; Citro ML; Keefer LK; Knaus EE
J Med Chem; 2008 Mar; 51(6):1954-61. PubMed ID: 18314945
[TBL] [Abstract][Full Text] [Related]
40. PABA/NO lead optimization: Improved targeting of cytotoxicity to glutathione S-transferase P1-overexpressing cancer cells.
Kim Y; Maciag AE; Cao Z; Deschamps JR; Saavedra JE; Keefer LK; Holland RJ
Bioorg Med Chem; 2015 Aug; 23(15):4980-4988. PubMed ID: 26043946
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
